TY  - JOUR
AU  - Ruiz-Villaverde, Ricardo
AU  - Rodriguez-Fernandez-Freire, Lourdes
AU  - Armario-Hita, Jose Carlos
AU  - Pérez-Gil, Amalia
AU  - Chinchay, Fiorella Vasquez
AU  - Galán-Gutiérrez, Manuel
PY  - 2022
DO  - 10.1111/dth.15760
UR  - http://hdl.handle.net/10668/19939
T2  - Dermatologic therapy
AB  - The IL23/Th17 axis plays a strategic role in psoriasis (PSO). Guselkumab (GUS) is a selective inhibitor of the IL23p19 subunit. Its introduction has managed to increase the levels of efficacy, safety and survival in PSO. In real clinical practice,...
LA  - en
KW  - Guselkumab
KW  - psoriasis
KW  - real world evidence
KW  - switching
KW  - Antibodies, Monoclonal
KW  - Antibodies, Monoclonal, Humanized
KW  - Humans
KW  - Pruritus
KW  - Psoriasis
KW  - Retrospective Studies
KW  - Severity of Illness Index
KW  - Treatment Outcome
KW  - Tumor Necrosis Factor Inhibitors
TI  - Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis.
TY  - research article
VL  - 35
ER  -